Infectious Disease & Vaccines

Strategies including parasite-based vaccines, mosquito-transmission blockers, and antibody drugs are promising new ways to target the disease.  

Real-world data and KOL insights highlight MeMed BV’s supportive role in emergency medicine

Vertex-Enlaza autoimmune drugs, DNA-wrapped CRISPR, HHS staff demand Kennedy’s resignation, and more lead the news this week.

After decades of stalled innovation, a new oral antibiotic could now combat both everyday infections and urgent public health threats.

Industry experts and consulting firms warn that proposed import tariffs could drive up drug prices, disrupt global supply chains, and divert investment away from critical R&D pipelines.

The ABX-01 is a broad-spectrum antimicrobial specifically selected to combat clinically prevalent and multidrug-resistant bacterial strains.

Paper presents the first pre-clinical application of endogenous antibody recruitment to address multi-drug resistant Gram-negative infections

Explore how broadly neutralizing antibodies (bNAbs) are offering a new path to an HIV cure by targeting the latent HIV reservoir and preventing transmission.

Explore how the immune system battles mold in lungs. A new study reveals a key cytokine, GM-CSF, helps immune cells clear the dangerous fungal spores.

Collaboration to leverage Oxford Nanopore’s sequencing platform and Cepheid’s GeneXpert system to advance the field of sequencing for infectious diseases.

Researchers are developing new, portable breath analysis tools to diagnose tuberculosis and other diseases, making screenings more accessible in remote areas and beyond.

A new antifungal drug, mandimycin, tackles resistant fungal strains with a never-before-seen mechanism that avoids kidney toxicity.